KIRKLAND, QC, Sept. 15, 2020 /CNW/ - Merck Canada Inc., an affiliate of Merck & Co., Inc., known as MSD outside the United States and Canada, announced today that Health Canada has approved BRENZYS, a TNF-inhibitor, for four new indications:
BRENZYS is a type of protein called a tumour necrosis factor (TNF) blocker that blocks the action of a substance the body makes called TNF-alpha. TNF-alpha is made by the body's immune system.5 People with immune diseases like JIA, PsA and PsO have too much TNF-alpha in their bodies, which can cause inflammation and lead to painful, swollen joints and raise thick, red, scaly patches ("psoriatic skin lesions") that can appear anywhere on the body.6 It can reduce the amount of TNF in the body to normal levels, helping to treat joint damage and psoriatic skin conditions. 7
An estimated one million Canadians live with psoriasis,8 and between 10 and 30% of these patients will develop psoriatic arthritis.9 Plaque Psoriasis is an inflammatory disease that affects the skin and can cause psoriatic skin lesions that can appear anywhere on the body.10 About 80% to 90% of people with psoriasis have plaque psoriasis, the most common type of psoriasis.11 PsA is usually seen in patients with PsO and affects both the joints and the skin.12 JIA is an inflammatory disease that affects the joints in the body and is the most common type of arthritis in children under the age of 16.13 Approximately 10,000 children and teens live with arthritis in Canada.14
"Merck is committed to providing Canadians with more therapeutic choices for patients and their treaters," says AnnA Van Acker, President, Merck Canada. "BRENZYS adds to Merck's portfolio of treatments for dermatological and inflammatory immune diseases and can help improve quality of life for patients living with psoriasis, psoriatic arthritis or juvenile idiopathic arthritis, as well as rheumatoid arthritis and ankylosing spondylitis."
About BRENZYS
BRENZYS is a biosimilar biologic drug (biosimilar)15 and authorized based on its similarity to ENBREL, which is already approved for use for PsO, PsA and JIA in Canada.16 A biosimilar is a biologic drug that is highly similar to a biologic drug already authorized for sale.17 Biosimilars are assessed and approved by Health Canada against the same meticulous standards used to ensure the quality, efficacy and safety of all other biologic drugs.18 Biosimilars provide patients more treatment options to help manage their disease and symptoms.
In addition to its use for the treatment of JIA, PsO and PsA, BRENZYS was first approved by Health Canada in 2016 for the treatment of moderate-to-severe rheumatoid arthritis (RA) in adults and ankylosing spondylitis (AS).19 It is administered by an injection under the skin and should be used under the guidance and supervision of a physician.20
Clinical efficacy and safety studies have been conducted in patients with rheumatoid arthritis to demonstrate clinical comparability between BRENZYS and ENBREL. The extrapolation of these data to support uses of BRENZYS in ankylosing spondylitis is based on the demonstrated comparability, in terms of product quality, non-clinical, human pharmacokinetic and clinical characteristics. Randomized clinical trials have not been conducted to compare BRENZYS to Enbrel in patients with psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, juvenile idiopathic arthritis and pediatric psoriasis.21
The most common expected adverse reactions with BRENZYS are infections, injection site reactions and headaches. It should not be administered to patients with or at risk of sepsis. BRENZYS contains a Boxed Warning to alert health care professionals and patients about an increased risk of serious infections including tuberculosis and infections caused by bacteria, viruses or fungi that have spread throughout their body. The Boxed Warning also notes that malignancies, sometimes fatal, have been reported in children and teenage patients who started using TNF-blocking agents, including etanercept, at less than 18 years of age.22
About Merck
For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals including cancer, infectious diseases such as HIV and Ebola and emerging animal diseases as we aspire to be the premier research-intensive biopharmaceutical company in the world.
In Canada, Merck markets a broad range of vaccines, pharmaceutical and animal health products and is one of the top R&D investors in Canada, with investments totaling $89 million in 2019 and more than $1.3 billion since 2000. Based in Kirkland, Qubec, Merck employs approximately 650 people across the country. For more information about our operations in Canada, visit http://www.merck.ca and connect with us on YouTube and Twitter @MerckCanada.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2017 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
Please see the product monograph for BRENZYS (etanercept injection) at:
https://www.merck.ca/static/pdf/BRENZYS-PM_E.pdf
References
1 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
2 Psoriasis. Canadian Dermatology Foundation. 2020.
3 Psoriatic Arthritis. Arthritis Society. 2020. https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis
4 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
5 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
6 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
7 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
8 Psoriasis. Canadian Dermatology Foundation. 2020.
9 Psoriatic Arthritis. Arthritis Society. 2020. https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis
10 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
11 Symptoms. Canadian Association of Psoriasis Patients. 2014. canadianpsoriasis.ca/index.php/en/psoriasis/81-english/psoriasis/94-symptoms#:~:text=About%2080%25%20to%2090%25%20of,with%20silvery%20scales%20on%20top
12 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
14 6 facts about Juvenile Idiopathic Arthritis. Montreal Children's Hospital. 2020. https://www.thechildren.com/health-info/conditions-and-illnesses/6-facts-about-juvenile-idiopathic-arthritis
15 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
16 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
17 Biosimilar Biologic Drugs in Canada: Fact Sheet. Government of Canada. August 27, 2019.
18 Biosimilar Biologic Drugs in Canada: Fact Sheet. Government of Canada. August 27, 2019.
19 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
20 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
21 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
22 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.
SOURCE Merck
Company Codes: NYSE:MRK
View original post here:
BRENZYS (etanercept injection) now indicated for the Treatment of Plaque Psoriasis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis - BioSpace
- The Compression Fracture of Thoracic Spine Due to Methotrexate-Associated Lymphoproliferative Disorder in Rheumatoid Arthritis: A Case Report - Cureus - February 15th, 2025
- Rheumatoid arthritis tied to cognitive decline in dementia - Medical Xpress - February 15th, 2025
- Tools and Devices to Improve Life and Mobility With Arthritis - U.S. News & World Report - February 15th, 2025
- Actor Adam Thomas Reveals How 'Eating Nothing But Meat and Eggs' is Easing his Arthritis Pain But These Are the Risks - Men's Health UK - February 15th, 2025
- New insights into the association between arthritis and overactive bladder in NHANES 20052020 - Nature.com - February 15th, 2025
- Rheumatoid Arthritis Treatment Market to Hit US$ 79.1 Billion - openPR - February 15th, 2025
- Psoriatic Disease, TNF Inhibitors, and Risk of Major Adverse Events - Medpage Today - February 15th, 2025
- The best treatments for arthritic knees if you want to avoid knee replacement surgery - The Telegraph - February 15th, 2025
- Early Launch Metrics Indicate UCBs Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market - GlobeNewswire - February 15th, 2025
- Rosnilimab shows promise in rheumatoid arthritis trial - Investing.com - February 15th, 2025
- 5 foods that keep your joints strong and healthy - Mint - February 15th, 2025
- If You Have Arthritis, This New Makeup Brand Is for You - Money Talks News - February 15th, 2025
- Lower Your Risk Of Rheumatoid Arthritis With These 5 Basic Habits - mindbodygreen - February 15th, 2025
- 'I treat top athletes with arthritis - cupboard staple ingredients are quite effective for pain and swelling' - GB News - February 15th, 2025
- AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment - Yahoo - February 15th, 2025
- Rheumatology enters the chat: research projects use AI and collaborative thinking to improve patient care - University of Alberta - February 15th, 2025
- In Patients with HS, a Closer Look at Stigmatization and Perceived Health Status - Medpage Today - February 15th, 2025
- Psoriatic Arthritis Treatment Market is Set To Fly High in Years to Come: AbbVie Inc., Amgen Inc., Johnson & - EIN News - February 15th, 2025
- Sandoz Rolls Out Rival Version Of AbbVie's Arthritis Drug Humira - BW Healthcare World - February 15th, 2025
- GSK To Bounce Regulatory Submissions For Experimental Arthritis Drug - BW Healthcare World - February 15th, 2025
- Living With Arthritis: Health Information Basics for You and Your ... - January 27th, 2025
- Rheumatoid Arthritis: Diagnosis, Treatment, and Steps to Take - January 27th, 2025
- Rheumatoid Arthritis | Health Topics | NIAMS - January 27th, 2025
- 6 Things to Know About Psoriatic Arthritis - Hartford HealthCare - January 27th, 2025
- MAPK4 inhibits the early aberrant activation of B cells in rheumatoid arthritis by promoting the IRF4-SHIP1 signaling pathway - Nature.com - January 27th, 2025
- Rheumatoid Arthritis Basics: Overview, Symptoms, and Causes - January 27th, 2025
- 8 Things You Should Do in Your 20s, 30s, and 40s to Prevent Joint Pain Later in Life - Self - January 27th, 2025
- 8 Natural Remedies to Relieve Join Pain and Improve Mobility - Health.com - January 27th, 2025
- East Texas vet tells what to watch for during cold weather in arthritic pets - KTRE - January 27th, 2025
- Research Shows a Link Between Inflammation in the Gut and Rheumatoid Arthritis - Health Central - January 27th, 2025
- Address to the Business Community Attend the Arthritis Foundation Event - TAPinto.net - January 27th, 2025
- The journey of 2-year-old with arthritis - PAHomePage.com - January 27th, 2025
- East Texas vet tells what to watch for during cold weather in arthritic pets - KLTV - January 27th, 2025
- Four tips for managing rheumatoid arthritis in the winter - Yahoo Lifestyle UK - January 27th, 2025
- Living with arthritis: Here's how diet, exercise, and daily habits can ease the pain - Moneycontrol - January 27th, 2025
- Sichuan wildlife park peddles tiger urine, claiming efficacy for rheumatoid arthritis, other conditions - Global Times - January 27th, 2025
- Non-surgical option to ease knee arthritis - The Week - January 27th, 2025
- Ease arthritis pain by adding 1 juice to your diet - Surrey Live - January 27th, 2025
- Four tips for managing rheumatoid arthritis in the winter - Yahoo News UK - January 27th, 2025
- Drinking one juice can ease arthritis pain, studies reveal - Daily Record - January 27th, 2025
- Annual Health Observances | NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - October 6th, 2024
- Obesity dampens rheumatoid arthritis treatment effectiveness, satisfaction - Healio - October 6th, 2024
- Patient Perspectives: Finding Grace While Living With Rheumatoid Arthritis - Rheumatology Advisor - October 6th, 2024
- Rheumatoid arthritis tied to heavy economic and human burdens - Medical Xpress - October 6th, 2024
- Dual therapy can have synergistic effect in difficult-to-treat inflammatory diseases - Healio - October 6th, 2024
- Hand-Held Scanner Could Transform Cancer and Arthritis Diagnosis - Technology Networks - October 6th, 2024
- Medical imaging breakthrough could transform cancer and arthritis diagnosis - University College London - October 6th, 2024
- Citryll and leading rheumatology centres receive - GlobeNewswire - October 6th, 2024
- Its going to be ubiquitous: Weight loss drugs may aid rheumatic disease treatment - Healio - October 6th, 2024
- Comorbidities Associated With Psoriasis: 5 Things to Know - Medscape - October 6th, 2024
- Opinion: Let's treat arthritis with the seriousness it deserves - Vancouver Sun - October 6th, 2024
- New handheld scanner technology could transform cancer and arthritis diagnosis - The Engineer - October 6th, 2024
- Stem cell therapy for osteoarthritis: Functional cartilage regeneration using 3d bioprinting technology - Open Access Government - October 6th, 2024
- Handheld scanner could transform cancer and arthritis diagnosis study - The Independent - October 6th, 2024
- Ankylosing Spondylitis and Self-Care: 6 Science-Backed Tips - Everyday Health - October 6th, 2024
- From a Labrador with arthritis to a goldfishs lifespan your pet queries answered... - The Sun - October 6th, 2024
- 15 Home Essentials That Make Life Easier If You Have Arthritis - HuffPost - September 21st, 2024
- Gout, a painful form of arthritis, is on the rise. Avoiding red meat and alcohol can help. - Yahoo Life - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pain - MedicineNet - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - U.S. News & World Report - September 21st, 2024
- Arthritis can flare up in colder weather: Tips to easing the pan - Medical Xpress - September 21st, 2024
- See how Waymo is bringing Arthritis Foundation of Arizona families to the ballpark - ABC15 Arizona in Phoenix - September 21st, 2024
- Prevalence of Loneliness in Inflammatory Arthritis and its Association with Disease Activity - Physician's Weekly - September 21st, 2024
- Psoriatic Arthritis and Gluten: Whats the Link? - Health Central - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Southernminn.com - September 21st, 2024
- 6 Knee Injuries That Can Cause Arthritis - Health News Hub - September 21st, 2024
- The Best Rheumatoid Arthritis Self-Care Tips To Soothe Painful Joints and Improve Mobility - Yahoo Life - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - El Paso Inc. - September 21st, 2024
- Shifting kneecap in kids? Early ligament repair can prevent arthritis in young Age: Experts - The Times of India - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Shelbynews - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Citizentribune - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - News-Daily.com - September 21st, 2024
- Casavant: Access to virtual care at risk for millions of arthritis patients - Daily Independent - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Avery Journal Times - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - The Elkhart Truth - September 21st, 2024
- What To Eat (And Skip) on a Rheumatoid Arthritis Diet To Reduce Painful Inflammation - Woman's World - September 21st, 2024
- Tiny knee bone linked to arthritis may have helped humans walk upright, scientists suggest - Sky News - September 13th, 2024
- Medical Marijuana Helps People With Arthritis And Other Rheumatic Conditions Reduce Use Of Opioids And Other Medications, Study Shows - Marijuana... - September 13th, 2024
- My 'stomach bug' turned out to be an agonising pain condition that left me wheelchair bound within four years - Daily Mail - September 13th, 2024
- Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis - Nature.com - September 13th, 2024